<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179295</url>
  </required_header>
  <id_info>
    <org_study_id>15091</org_study_id>
    <nct_id>NCT01179295</nct_id>
  </id_info>
  <brief_title>Japanese BAY86-9766 Monotherapy Phase I Study</brief_title>
  <official_title>Phase 1 Study of Single Agent BAY86-9766 in Japanese Patients With Advanced or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an uncontrolled, open-label, non-randomized phase I / pharmacokinetic study of oral
      BAY86-9766 to investigate the safety, tolerability, pharmacokinetics, and efficacy profiles
      in Japanese patients with advanced solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2010</start_date>
  <completion_date type="Actual">April 27, 2012</completion_date>
  <primary_completion_date type="Actual">April 27, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation due to results of physical examinations, vital signs, AEs, abnormal laboratory tests and 12-lead ECG, cardiac function test and ophthalmological examination.</measure>
    <time_frame>At the end of 30-day follow up after discontinuation of study drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Calculation of pharmacokinetic parameters of BAY86-9766 and its metabolite (M17).</measure>
    <time_frame>Cycle 1 Day 22 and Day 23 for Cohorts 1 &amp; 2 and Cohorts 3 &amp; 4, respectively.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>On average 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>On average 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY86-9766</intervention_name>
    <description>BAY86-9766 30 mg twice a day (bid).</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY86-9766</intervention_name>
    <description>BAY86-9766 50 mg twice a day (bid).</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY86-9766</intervention_name>
    <description>BAY86-9766 100 mg once a day (od)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY86-9766</intervention_name>
    <description>BAY86-9766 60 mg once a day (od)</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients, who are at least 18 years of age at the first screening
             examination/ visit, with advanced or refractory solid tumors not amenable to standard
             therapy.

          -  Histological or cytological documentation of non-hematologic, malignant solid tumor,
             excluding primary brain or spinal tumors, with no current involvement in the central
             nervous system (CNS)

          -  At least one measurable lesion or evaluable disease according to response evaluation
             criteria in solid tumors (RECIST) version 1.1

          -  Eastern cooperative oncology group performance status (ECOG-PS) of 0 or 1

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Use of any anti-cancer therapy including chemotherapy, investigational agents or
             devices and immunotherapy within 4 weeks of the first dose of study medication

          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or diastolic
             pressure &gt; 90 mmHg, despite optimal medical management

          -  Known human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C

          -  Inadequate bone marrow, liver and renal function

          -  Inability to swallow oral medications or any condition that could affect the
             absorption of orally administered drugs

          -  Concomitant treatment with cytochrome P450 isoenzymes CYP3A4 inhibitors/inducers, and
             CYP2C19 inhibitors/ inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEK inhibitor</keyword>
  <keyword>BAY86-9766</keyword>
  <keyword>RDEA 119</keyword>
  <keyword>Solid tumor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

